Therapeutic, diagnostic and prognostic values of TRIM proteins in prostate cancer

Pharmacol Rep. 2023 Nov 3. doi: 10.1007/s43440-023-00534-9. Online ahead of print.ABSTRACTProstate cancer is the second most prevalent cancer in men worldwide. The TRIM (tripartite motif) family of proteins is involved in the regulation of various cellular processes, including antiviral immunity, apoptosis, and cancer progression. In recent years, several TRIM proteins have been found to play important roles in prostate cancer initiation and progression. TRIM proteins have indicated oncogenic activity in prostate cancer by enhancing androgen or estrogen receptor signaling and promoting cancer cell growth. Inhibition of TRIM proteins has been raised as a potential therapeutic strategy for the treatment of prostate cancer. Overall, these studies suggest that TRIM family proteins exert tumor-promoting effects in prostate cancer, and targeting these proteins can provide a promising therapeutic strategy for prostate cancer treatment. On the other hand, some TRIM proteins can be differentially expressed in prostate cancer cells compared to normal cells, thus providing novel diagnostic/prognostic biomarkers for prostate cancer.PMID:37921966 | DOI:10.1007/s43440-023-00534-9
Source: Pharmacological Reports - Category: Drugs & Pharmacology Authors: Source Type: research